McCourt Marion 4
4 · REGENERON PHARMACEUTICALS, INC. · Filed Oct 3, 2024
Insider Transaction Report
Form 4
McCourt Marion
SVP Commercial
Transactions
- Sale
Common Stock
2024-10-01$1054.06/sh−1,000$1,054,060→ 12,931 total - Exercise/Conversion
Common Stock
2024-10-01$381.40/sh+1,000$381,400→ 13,931 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2024-10-01−1,000→ 7,000 totalExercise: $381.40Exp: 2028-12-12→ Common Stock (1,000 underlying)
Holdings
- 174(indirect: By 401(k))
Common Stock
Footnotes (2)
- [F1]Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2024.
- [F2]The stock option award vests in four equal annual installments, commencing one year after the date of grant.